Stereodivergent Total Syntheses of (+)‐Monomorine I and (+)‐Indolizidine 195B
作者:Rafid S. Dawood、Robert A. Stockman
DOI:10.1002/ejoc.202100453
日期:2021.7.22
Diastereoselective addition to a single sulfinimine allows for stereodivergeant synthetic approaches towards two related natural products monomorine and indolizidine 195B via closed or open transition states.
Cu-Catalyzed Conjugate Addition of Grignard Reagents to Thiochromones: An Enantioselective Pathway for Accessing 2-Alkylthiochromanones
作者:Qingxiong Yang、Jun Wang、Shihui Luo、Ling Meng
DOI:10.1055/s-0037-1610225
日期:2018.9
The enantioselective incorporation of alkyl groups in thiochromones was realized for the first time by a Cu/(R,S)-PPF-P t Bu2-catalyzed conjugate addition of Grignardreagents to thiochromones. With this method, a series of 2-methylthiochromanones were obtained in good yields (up to 96% yield) with moderate-to-good ee values (up to 87% ee). The established method expedites the synthesis of a large
通过Cu/(R,S)-PPF-P t Bu2 催化的格氏试剂与硫色酮的共轭加成,首次实现了烷基在硫色酮中的对映选择性掺入。使用这种方法,以良好的收率(最高 96% 的收率)获得了一系列 2-甲基硫代色满酮,其 ee 值中等至良好(最高 87% ee)。已建立的方法加速了大型手性硫代色满酮库的合成,以用于进一步的合成应用和生物学研究。
Total synthesis of pleosporol A and its stereoisomers
作者:Hangfei Mao、Pin-Mei Wang、Jinzhong Xu
DOI:10.1016/j.tet.2020.131913
日期:2021.2
The cyclohexenone derivatives pleosporols A, B and stemfolone B were reported as novel antibacterial agents. In this study, we reported the first total synthesis of pleosporol A and itsstereoisomers from arabinose, utilizing intramolecular nitrone-alkene cycloaddition and Hofmann elimination under Swern condition for constructing the cyclohexene ring.
[EN] HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS<br/>[FR] DÉRIVÉS AROMATIQUES HÉTÉROBICYCLIQUES ET HÉTÉROAROMATIQUES POUR LE TRAITEMENT DE TROUBLES LIÉS À LA FERROPTOSE
申请人:COLLABORATIVE MEDICINAL DEV LLC
公开号:WO2020185738A1
公开(公告)日:2020-09-17
The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.